Clinical Policy: Siltuximab (Sylvant)
Clinical coverage policy for siltuximab (Sylvant) detailing initial and continued therapy criteria for multicentric Castleman's disease (MCD), off-label use for unicentric Castleman's disease (UCD) and cytokine release syndrome (CRS), contraindications, dosing limits, required documentation, and coding implications for Health Net / Centene lines of business (HIM, Medicaid).
Added NCCN-supported use for CRS to allow Sylvant as replacement for second dose of Actemra or Tofidence; later added Tyenne and Carvykti examples.
Lab parameters removed from criteria sets as they do not represent treatment contraindication.
Added criteria set for NCCN compendium-supported use for CRS associated with CAR or autologous T cell therapy.
Minor template and reference updates with no significant clinical policy changes in 1Q2023 review.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.